Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

neurodegenerative diseases

- PMLiVE

Newron back on track for Xadago approval in US

Italian firm is not required to conduct additional trials for its Parkinson’s disease drug

EU flag

EC approves Bial’s Parkinson’s disease therapy

Ongentys will be given a phase roll-out in 2016 and 2017

- PMLiVE

Nuplazid backed by FDA panel as first-ever Parkinson’s psychosis drug

Concludes Acadia Pharmaceuticals’ drug provides ‘modest but meaningful’ benefits

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

- PMLiVE

Acorda acquires Biotie to expand in Parkinson’s disease

Strikes $363m deal for Finnish firm

- PMLiVE

Michael J Fox Foundation backs wearable device trial

Partners with chip manufacturer Intel and Cynapsus Therapeutics on Parkinson's study

- PMLiVE

FDA approves AbbVie’s Duopa in advanced Parkinson’s

Drug is administered into the stomach via a tube

- PMLiVE

MRC Technology and Yabao form Parkinson’s partnership in China

Companies will target specific kinase involved in neurodegeneration

- PMLiVE

Charity coalition pledges millions for brain disease research

Will invest £30m developing candidates for neurodegenerative conditions

- PMLiVE

AbbVie-partnered Calico unveils first licensing deal

Google’s healthcare research business gains rights to drug prospects in neurodegeneration

- PMLiVE

Online Parkinson’s platform could revolutionise chronic disease care

ParkinsonNet connects patients with doctors in a virtual setting

Roche - Basel

Roche signs Parkinson’s deal with Prothena

Antibody development agreement is worth up to $600m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links